Process of treatment

Abstract

A process for inhibiting platelet aggregation by the addition of a member selected from the group consisting of a compound of the formula: ##STR1## wherein Y is lower alkyl of 1 to 8 carbon atoms, cyclopropyl, ethinyl, --CH.sub.3, --F, --Cl, --OCH.sub.3, --OCH.sub.2 OCH.sub.3, --SCH.sub.3, --SCHF.sub.2, --SCH.sub.2 OCH.sub.3, acetyl; R.sub.1 and R.sub.2 are H, CH.sub.3, CHF.sub.2, or taken together are .dbd.CH.sub.2 or .uparw.CF.sub.2 ; and X is hydrogen, lower alkyl of 1 to 8 carbon atoms or a pharmacologically acceptable cation, to in vivo and in vitro platlet systems. In vitro systems include whole blood as kept n blood banks, whole blood as used in heat-lung machines, and platelet rich cocentrates. In vivo systems include human or animal bodies. The process provides a means for treating hemorrhage due to thrombocytopenia which in turn is caused by irradiation, cancer chemotherapy, or immunosuppressants as well as hemophilia due to cogenital defects.

Dependencies are inferred from the claim text.